Guardant Health Inc

GH

Equity

ISIN null / Valor 43633454

NASDAQ (2025-11-19)

USD 99.55+4.16%

Guardant Health Inc
UMushroom community rating:

4.29 7 votes No rating yet

NegativeNeutralPositive

About company

Guardant Health Inc is a company that focuses on utilizing blood tests to provide valuable insights for improving clinical outcomes in cancer care. With over 500,000 tests performed by 12,000 doctors, their commercially available tests assist in treatment decisions for advanced cancer patients, monitoring treatment response, detecting residual and recurrent disease in early-stage cancer patients, and potentially screening for cancer before symptoms appear. Additionally, their products support pharmaceutical companies in developing innovative cancer therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Significant Revenue Growth

Revenue surged by 31% year-over-year to $232.1 million, driven by strong performances in Oncology, Screening, and Biopharma & Data segments. Specifically, Oncology revenue increased by 22% to $158.7 million, Screening revenue reached $14.8 million, and Biopharma & Data revenue grew by 28% to $56.0 million.

Raised 2025 Revenue Guidance

Guardant Health elevated its 2025 revenue outlook to a range of $915 million to $925 million, up from the previous guidance of $880 million to $890 million. This adjustment reflects an anticipated growth of 24% to 25%, compared to the earlier projection of 19% to 20%.

Improved Gross Margin

The company achieved a non-GAAP gross margin of 66%, a notable increase from 60% in the second quarter of 2024, highlighting enhanced operational efficiency and higher average selling prices.

Product Innovation and Expansion

Guardant Health introduced 11 new Smart Liquid Biopsy applications for Guardant360 Liquid and expanded its Oncology offerings with Guardant Hereditary Cancer Testing and a suite of immunohistochemistry tests, reinforcing its position as a leader in precision oncology.

Summarized from source with an LLMView Source

Key figures

224%1Y

107%3Y

-8.26%5Y

Performance

62.0%1Y

66.9%3Y

67.9%5Y

Volatility